한글목차

GLP-1 수용체 작용제의 동향과 예측

세계의 GLP-1 수용체 작용제 시장은 2024-2030년의 CAGR이 6.0%로, 2030년까지 추정 251억 달러에 달할 것으로 예측됩니다. 이 시장의 주요 촉진요인은 2형 당뇨병, 비만 및 관련 질환의 증례 증가, 건강하지 못한 라이프스타일에 대한 적응의 증가, 당뇨병 질환의 유전력 및 고령화 인구의 증가입니다. 세계의 GLP-1 수용체 작용제 시장의 미래는 병원과 전문 클리닉 시장의 기회에 의해 유망시되고 있습니다.

GLP-1 수용체 작용제 시장 인사이트

Lucintel은 비만율의 증가, 2형 당뇨병 유전적 리스크 요인의 증가에 의해 Dulaglutide가 예측 기간 중 최대 부문을 유지할 것으로 예측하고 있습니다.

북미는 연구개발의 확대 및 헬스케어 시설의 증가에 의해 예측 기간 중에도 최대 지역을 유지할 것입니다.

자주 묻는 질문

Q1.시장 규모는?

A1.세계의 GLP-1 수용체 작용제 시장은 2030년까지 추정 251억 달러에 달할 것으로 예상되고 있습니다.

Q2.시장의 성장 예측은?

A2.세계의 GLP-1 수용체 작용제 시장은 2024-2030년 CAGR 6.0%로 성장할 것으로 예측됩니다.

Q3.시장의 성장에 영향을 미치는 주요 촉진요인은?

A3.이 시장의 주요 촉진요인은 2형 당뇨병, 비만 및 관련 질환의 증례 증가, 건강하지 못한 라이프스타일에 대한 적응의 증가, 당뇨병 질환의 유전력 및 고령화 인구의 증가입니다.

Q4.시장의 주요 부문은?

A4.세계의 GLP-1 수용체 작용제 시장의 미래는 병원과 전문 클리닉 시장 기회가 유망합니다.

Q5.시장의 주요 기업은?

A5.GLP-1 수용체 작용제의 주요 기업은 다음과 같습니다.

• F. Hoffmann-La Roche
• Bristol-Myers Squibb Company
• Astrazeneca
• Pfizer
• Baxter
• Hikma Pharmaceuticals
• Amneal Pharmaceuticals
• Teva Pharmaceuticals
• Sun Pharmaceuticals
• Mylan

Q6.향후 최대가 되는 시장 부문은?

A6.Lucintel은 비만율의 증가, 2형 당뇨병 유전적 위험 요인의 증가에 의해 Dulaglutide가 예측 기간 중 최대 부문을 유지할 것으로 예측하고 있습니다.

Q7.시장에서 향후 5년간 최대가 될 것으로 예상되는 지역은?

A7.북미는 연구개발의 확대와 헬스케어 시설의 증가에 의해 예측 기간 중에도 최대 지역을 유지합니다.

Q8.리포트의 커스터마이즈는 가능한가?

A8.네, Lucintel은 추가 비용 없이 10%의 커스터마이즈를 제공합니다.

목차

제1장 주요 요약

제2장 세계의 GLP-1 수용체 작용제 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계의 촉진요인과 과제

제3장 2018-2030년의 시장 동향과 예측 분석

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 GLP-1 수용체 작용제 시장 동향(2018-2023년) 및 예측(2024-2030년)
• 약물의 유형별 세계의 GLP-1 수용체 작용제 시장
  • Exenatide
  • Liraglutide
  • Lixisenatide
  • Dulaglutide
• 브랜드별 세계의 GLP-1 수용체 작용제 시장
  • Byetta
  • Bydureon
  • Victoza
  • Trulicity
  • Lyxumia
• 투여 경로별 세계 GLP-1 수용체 작용제 시장
  • 경구
  • 비경구
  • 기타
• 최종 용도별 세계 GLP-1 수용체 작용제 시장
  • 병원
  • 전문 클리닉
  • 기타

제4장 2018-2030년의 지역별 시장 동향과 예측 분석

• 지역별 세계의 GLP-1 수용체 작용제 시장
• 북미의 GLP-1 수용체 작용제 시장
• 유럽의 GLP-1 수용체 작용제 시장
• 아시아태평양의 GLP-1 수용체 작용제 시장
• 기타 지역의 GLP-1 수용체 작용제 시장

제5장 경쟁의 분석

• 제품 포트폴리오 분석
• 운영상 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략적 분석

• 성장 기회 분석
  • 약물의 유형별 세계의 GLP-1 수용체 작용제 시장의 성장 기회
  • 브랜드별 세계의 GLP-1 수용체 작용제 시장의 성장 기회
  • 투여 경로별 세계 GLP-1 수용체 작용제 시장의 성장 기회
  • 최종 용도별 세계 GLP-1 수용체 작용제 시장의 성장 기회
  • 지역별 세계의 GLP-1 수용체 작용제 시장의 성장 기회
• 세계의 GLP-1 수용체 작용제 시장의 새로운 동향
• 전략적 분석
  • 신제품 개발
  • 세계의 GLP-1 수용체 작용제 시장의 능력 확대
  • 세계의 GLP-1 수용체 작용제 시장에서의 합병, 인수, 합병사업
  • 인증과 라이선싱

제7장 유력 기업의 기업 개요

• F. Hoffmann-La Roche
• Bristol-Myers Squibb Company
• AstraZeneca
• Pfizer
• Baxter
• Hikma Pharmaceuticals
• Amneal Pharmaceuticals
• Teva Pharmaceuticals
• Sun Pharmaceuticals
• Mylan

영문목차

Glucagon-Like Peptide 1 Agonists Trends and Forecast

The future of the global glucagon-like peptide 1 agonists market looks promising with opportunities in the hospital and specialty clinic markets. The global glucagon-like peptide 1 agonists market is expected to reach an estimated $25.1 billion by 2030 with a CAGR of 6.0% from 2024 to 2030. The major drivers for this market are increase in the cases of type 2 diabetes, obesity and related disorders, increasing adaptation of unhealthy lifestyle and genetic history of diabetes disorders, as well as, growing aging population.

A more than 150-page report is developed to help in your business decisions.

Glucagon-Like Peptide 1 Agonists by Segment

The study includes a forecast for the global glucagon-like peptide 1 agonists by drug type, brand, route of administration, end use, and region.

Glucagon-Like Peptide 1 Agonists Market by Drug Type [Shipment Analysis by Value from 2018 to 2030]:

• Exenatide
• Liraglutide
• Lixisenatide
• Dulaglutide

Glucagon-Like Peptide 1 Agonists Market by Brand [Shipment Analysis by Value from 2018 to 2030]:

• Byetta
• Bydureon
• Victoza
• Trulicity
• Lyxumia

Glucagon-Like Peptide 1 Agonists Market by Route of Administration [Shipment Analysis by Value from 2018 to 2030]:

• Oral
• Parenteral
• Others

Glucagon-Like Peptide 1 Agonists Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals
• Specialty Clinics
• Others

Glucagon-Like Peptide 1 Agonists Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Glucagon-Like Peptide 1 Agonists Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies glucagon-like peptide 1 agonists companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the glucagon-like peptide 1 agonists companies profiled in this report include-

• F. Hoffmann-La Roche
• Bristol-Myers Squibb Company
• Astrazeneca
• Pfizer
• Baxter
• Hikma Pharmaceuticals
• Amneal Pharmaceuticals
• Teva Pharmaceuticals
• Sun Pharmaceuticals
• Mylan

Glucagon-Like Peptide 1 Agonists Market Insights

Lucintel forecasts that dulaglutide will remain the largest segment over the forecast period due to growing obesity rates, and increasing genetic risk factors for type 2 diabetes.

North America will remain the largest region over the forecast period due to the expansion of research and development, as well as growing healthcare facilities in the region.

Features of the Global Glucagon-Like Peptide 1 Agonists Market

Market Size Estimates: Glucagon-like peptide 1 agonists market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Glucagon-like peptide 1 agonists market size by various segments, such as by drug type, brand, route of administration, end use, and region in terms of value ($B).

Regional Analysis: Glucagon-like peptide 1 agonists market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug type, brand, route of administration, end use, and regions for the glucagon-like peptide 1 agonists market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the glucagon-like peptide 1 agonists market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the glucagon-like peptide 1 agonists market size?

Answer: The global glucagon-like peptide 1 agonists market is expected to reach an estimated $25.1 billion by 2030.

Q2. What is the growth forecast for glucagon-like peptide 1 agonists market?

Answer: The global glucagon-like peptide 1 agonists market is expected to grow with a CAGR of 6.0% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the glucagon-like peptide 1 agonists market?

Answer: The major drivers for this market are increase in the cases of type 2 diabetes, obesity and related disorders, increasing adaptation of unhealthy lifestyle and genetic history of diabetes disorders, as well as, growing aging population.

Q4. What are the major segments for glucagon-like peptide 1 agonists market?

Answer: The future of the global glucagon-like peptide 1 agonists market looks promising with opportunities in the hospital and specialty clinic markets.

Q5. Who are the key glucagon-like peptide 1 agonists market companies?

Answer: Some of the key glucagon-like peptide 1 agonists companies are as follows.

• F. Hoffmann-La Roche
• Bristol-Myers Squibb Company
• Astrazeneca
• Pfizer
• Baxter
• Hikma Pharmaceuticals
• Amneal Pharmaceuticals
• Teva Pharmaceuticals
• Sun Pharmaceuticals
• Mylan

Q6. Which glucagon-like peptide 1 agonists market segment will be the largest in future?

Answer: Lucintel forecasts that dulaglutide will remain the largest segment over the forecast period due to growing obesity rates, and increasing genetic risk factors for type 2 diabetes.

Q7. In glucagon-like peptide 1 agonists market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to the expansion of research and development, as well as growing healthcare facilities in the region.

Q8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the glucagon-like peptide 1 agonists market by drug type (exenatide, liraglutide, lixisenatide, and dulaglutide), brand (byetta, bydureon, victoza, trulicity, and lyxumia), route of administration (oral, parenteral, and others), end use (hospitals, specialty clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Glucagon-Like Peptide 1 Agonists Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Glucagon-Like Peptide 1 Agonists Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Glucagon-Like Peptide 1 Agonists Market by Drug Type
  • 3.3.1: Exenatide
  • 3.3.2: Liraglutide
  • 3.3.3: Lixisenatide
  • 3.3.4: Dulaglutide
• 3.4: Global Glucagon-Like Peptide 1 Agonists Market by Brand
  • 3.4.1: Byetta
  • 3.4.2: Bydureon
  • 3.4.3: Victoza
  • 3.4.4: Trulicity
  • 3.4.5: Lyxumia
• 3.5: Global Glucagon-Like Peptide 1 Agonists Market by Route of Administration
  • 3.5.1: Oral
  • 3.5.2: Parenteral
  • 3.5.3: Others
• 3.6: Global Glucagon-Like Peptide 1 Agonists Market by End Use
  • 3.6.1: Hospitals
  • 3.6.2: Specialty Clinics
  • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Glucagon-Like Peptide 1 Agonists Market by Region
• 4.2: North American Glucagon-Like Peptide 1 Agonists Market
  • 4.2.2: North American Glucagon-Like Peptide 1 Agonists Market by End Use: Hospitals, Specialty Clinics, and Others
• 4.3: European Glucagon-Like Peptide 1 Agonists Market
  • 4.3.1: European Glucagon-Like Peptide 1 Agonists Market by Drug Type: Exenatide, Liraglutide, Lixisenatide, and Dulaglutide
  • 4.3.2: European Glucagon-Like Peptide 1 Agonists Market by End Use: Hospitals, Specialty Clinics, and Others
• 4.4: APAC Glucagon-Like Peptide 1 Agonists Market
  • 4.4.1: APAC Glucagon-Like Peptide 1 Agonists Market by Drug Type: Exenatide, Liraglutide, Lixisenatide, and Dulaglutide
  • 4.4.2: APAC Glucagon-Like Peptide 1 Agonists Market by End Use: Hospitals, Specialty Clinics, and Others
• 4.5: ROW Glucagon-Like Peptide 1 Agonists Market
  • 4.5.1: ROW Glucagon-Like Peptide 1 Agonists Market by Drug Type: Exenatide, Liraglutide, Lixisenatide, and Dulaglutide
  • 4.5.2: ROW Glucagon-Like Peptide 1 Agonists Market by End Use: Hospitals, Specialty Clinics, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Glucagon-Like Peptide 1 Agonists Market by Drug Type
  • 6.1.2: Growth Opportunities for the Global Glucagon-Like Peptide 1 Agonists Market by Brand
  • 6.1.3: Growth Opportunities for the Global Glucagon-Like Peptide 1 Agonists Market by Route of Administration
  • 6.1.4: Growth Opportunities for the Global Glucagon-Like Peptide 1 Agonists Market by End Use
  • 6.1.5: Growth Opportunities for the Global Glucagon-Like Peptide 1 Agonists Market by Region
• 6.2: Emerging Trends in the Global Glucagon-Like Peptide 1 Agonists Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Glucagon-Like Peptide 1 Agonists Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Glucagon-Like Peptide 1 Agonists Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: F. Hoffmann-La Roche
• 7.2: Bristol-Myers Squibb Company
• 7.3: AstraZeneca
• 7.4: Pfizer
• 7.5: Baxter
• 7.6: Hikma Pharmaceuticals
• 7.7: Amneal Pharmaceuticals
• 7.8: Teva Pharmaceuticals
• 7.9: Sun Pharmaceuticals
• 7.10: Mylan